Nuwellis, INC

Nuwellis, Inc. held a special meeting where stockholders approved the issuance of shares related to warrant exercises and a reverse stock split to meet Nasdaq listing requirements.

Nuwellis, Inc. announced the successful closing of its registered public offering, raising approximately $6.0 million in gross proceeds.

Nuwellis, Inc. announced its first quarter 2026 financial results, reporting a 26% increase in net sales to $2.4 million and improved gross margin to 70.1%.

Nuwellis, Inc. held its annual meeting on April 28, 2026, where stockholders elected two Class I directors and ratified Baker Tilly US, LLP as the independent auditor for fiscal year 2026.

Nuwellis, Inc. has reached a settlement agreement to resolve a breach of contract lawsuit filed by E.F. Hutton & Co.

Nuwellis, Inc. filed an amended 8-K to include response letters from two former directors who dispute the company's characterization of their resignations.

Nuwellis reports Q1 2026 revenue growth of 26.2% alongside the acquisition of Rendiatech to expand its cardiorenal platform.

Nuwellis, Inc. reported a widened net loss for the nine months ended September 30, 2025, alongside strategic realignments including exiting international operations and terminating a clinical trial, while actively raising capital.

Nuwellis, Inc. reported a wider net loss in Q2 2025, implemented a reverse stock split, and exited international operations while terminating a clinical trial to focus on core U.S. markets.

Nuwellis, Inc. reports its financial results for the first quarter of 2025, highlighting a slight increase in net sales but continued losses and efforts to secure additional capital.

Nuwellis, a medical device company, announced its Q3 2024 results, showing a slight decrease in net sales but a significant improvement in net income due to warrant liability adjustments, while also detailing cost-cutting measures and recent capital raising activities.

Nuwellis, Inc. announces its Q2 2024 financial results, highlighting a slight increase in net sales but significant losses and ongoing efforts to address financial instability.

Nuwellis, Inc. files its 10-K, highlighting its focus on the Aquadex System for treating fluid overload and its commercial activities in heart failure, critical care, and pediatrics.

Nuwellis, Inc.'s 10-K filing outlines the terms of its common and preferred stock, including voting rights, dividend entitlements, and anti-takeover provisions.

Director Gregory D. Waller was granted 6,744 nonstatutory stock options in Nuwellis, Inc. as part of standard compensation.

Martin J. Emerson, a Director at Nuwellis, Inc., acquired 6,744 non-statutory stock options on April 28, 2026, as detailed in a recent SEC Form 4 filing.

Nuwellis, Inc. reports that Director Archelle Georgiou Feldshon acquired 6,744 non-statutory stock options on April 28, 2026.

Nuwellis, Inc. director David McDonald acquired 6,744 stock options with an exercise price of $1.16, vesting over 12 months.

Nuwellis, Inc. CEO and President John L. Erb was granted 115,329 incentive stock options with an an exercise price of $0.2377, vesting over 12 months.

Nuwellis, Inc.'s CEO and 10% owner, John L. Erb, has restructured his preferred stock holdings by exchanging Series F for Series F-1 Convertible Preferred Stock and subsequently converting a portion into common shares.

Nuwellis, Inc. is holding a special meeting on July 24, 2026, to seek stockholder approval for the issuance of shares upon warrant exercise and a reverse stock split to maintain Nasdaq compliance.

Nuwellis, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for April 28, 2026, to elect two Class I directors and ratify the appointment of its independent auditor.

Nuwellis, Inc. is convening a special stockholder meeting to vote on proposals crucial for its financial flexibility and continued Nasdaq listing, including warrant exercise approval, an increase in authorized shares, and a potential reverse stock split.

Nuwellis, Inc. is asking stockholders to approve a reverse stock split to maintain its Nasdaq listing, alongside other corporate governance matters at the upcoming annual meeting.

Nuwellis, Inc. is asking stockholders to approve a reverse stock split to comply with Nasdaq's continued listing requirements at the annual meeting on May 20, 2025.

Nuwellis, Inc. is holding its 2024 annual meeting of stockholders on June 6, 2024, to vote on key proposals including a reverse stock split, executive compensation, and approval of anti-dilution provisions in common warrants.

Nuwellis, Inc. has filed a registration statement to register an additional $5.05 million in common stock and warrants following a previous offering.

Nuwellis, Inc. has filed an S-1/A registration statement detailing an offering of common stock and accompanying warrants, outlining terms and conditions for investors.

Nuwellis, Inc. is conducting a reasonable best efforts offering of common stock and warrants to raise capital for working capital and general corporate purposes.

Nuwellis, Inc. has filed a registration statement for a best-efforts offering of common stock and warrants to raise approximately $4.4 million in net proceeds.

Nuwellis, Inc., a medical technology company, is launching a public offering of common stock and warrants to raise approximately $4.2 million for working capital and potential acquisition activities, while facing significant financial challenges including accumulated deficits and ongoing Nasdaq listing compliance issues.

Nuwellis, Inc. has filed an S-1 registration statement to offer common stock and warrants, aiming to raise approximately $4.2 million for working capital and potential acquisition activities, despite ongoing operating losses and substantial doubt about its ability to continue as a going concern.

Nuwellis, Inc. CEO John L. Erb has significantly increased his beneficial ownership in the company to 7.3% of common stock after converting Series F-1 Convertible Preferred Stock for investment purposes.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 7.11% of Nuwellis, Inc. common stock as of March 31, 2026.

Sabby Management, LLC, Hal Mintz, and Sabby Volatility Warrant Master Fund, Ltd. have reported a 5.4% beneficial ownership stake in Nuwellis, Inc. common stock.

A group comprising Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC has disclosed a passive beneficial ownership of 4.99% of Nuwellis, Inc.'s common stock as of June 13, 2025, following an underwritten public offering.

A group of investment funds and their managing member, Michael Bigger, have reported the sale of their entire beneficial ownership in Nuwellis, Inc. common stock and pre-funded warrants, reducing their stake to below 5%.

S.H.N. Financial Investments Ltd. has filed an amended Schedule 13G, indicating that it no longer beneficially owns any shares of Nuwellis, Inc. as of December 31, 2024.